5Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glnides in the treatment of type 2diabetes mellitus [ J ]. Exp Clin Endocrinol Diabetes, 2000,108: 151.
6Wagstaff A J, Goa KL. Rosiglitazone:a review of its use in the management of type 2 diabetes mellitus [ J ]. Drugs, 2002,62:1806.
7Yki - Jarvinen H. Thiazolidinediones[ J]. NEJM, 2004,351:1 106.
8Canadian Adverse Drug Reaction Monitoring Program.Rosiglitazone:hepatic,cardiac and hematolodical reactions[J].Canadian Advers Drug Reaction Newsletter, 2001,11: 2.
9Vu D, Murty M, McMorran M. Rosiglitazone and pioglitazone:update on cardiovascular and hepatic adverse reaction [J].Canadian Advers Drug Reaction Newsletter, 2002,12:2.
10Belcher G, Lambert C, Goh KL. et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide[J]. Int J Clin Pract , 2004,58:833.
二级参考文献17
1Izumi I, Hosiyama K, Enomoto S, et al. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J Pharmacol Exp Ther, 1997, 280:1392-1400.
2Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med, 2001, 111 :10-17.
3Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care , 2000, 23: 1605-1611.
4Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther, 2000 , 22: 1395-1409.
5Rubin C, Egan J, Schneider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes,1999 , 48 Suppl 1:A110.
6Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care, 1999, 22:288-293.
7Gillies PS, Dunn CJ. Pioglitazone. Drugs, 2000, 60:333-343.
8Hanefeld M. The metabolic syndrome: roots, myths and facts. In: Hanefeld M, Leonhardt W.eds. The metabolic syndrome. Jena: Gustav Fischer, 1997. 13-24.
9Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab, 1999, 1 Suppl 1:S1-7.
10Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest, 1994, 94:1714-1721.
6WIGG AJ,ROBERTS-THOMSON IC,DYMOCK RB,et al. The role of small intestinal overgrowth,intestinal permeability,endotoxaemia,and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis[J]. Gut,2001,48 (2):206.
7CASTRO CM,ERKELENS DW,VAN DIJK H,et al. Free fatty acids:mediators of insulin resistance and atherosclerosis [J]. Ned Tijdschr Geneskd,2002,146:103-109.
8BODEN G,SHE P,MOZZOLI M,et,al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver [J]. Diabetes, 2005,54 (12) : 3458-6.
9DAY CP. Pathogenesis of steatohepatitis [J]. Best Pract Res Clin Gastroenterol,2002,16(5) :663-678.
10KUGELMAS M,HILL DB,VIVIAN B,et al. Cytokines and NASH:a pilot study of the effects of lifestyle modification and vitamin E[J]. Hepatology,2003,38(2):413-419.
